Original Research
Hepatitis B and HIV co-infection in South Africa: Just treat it!
Submitted: 24 June 2019 | Published: 23 March 2009
About the author(s)
Cynthia S Firnhaber, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg; Right to Care, Johannesburg, South AfricaPrue Ive, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
Full Text:
PDF (264KB)Abstract
There are an estimated 350 million hepatitis B carriers worldwide. The prevalence of mono-infection with hepatitis B in South Africa has been estimated at approximately 10% for the rural population and 1% in urban areas. The transmission routes of hepatitis B and HIV are similar, but hepatitis B is more efficient. Co-infection with HIV and hepatitis B is therefore not unusual. Recent studies have shown that the prevalence of HIV/HBV co-infection (using HBV surface antigen (HBsAg) as a marker for HBV) in South Africa ranges from 4.8% to 17%, depending on the population studied.
The guidelines for the South African HIV Comprehensive Care, Management and Treatment (CCMT) programme do not include viral hepatitis studies. Hepatitis B serology is usually done only if serum aminotransferases are evaluated in the absence of another known cause (e.g. tuberculosis and concomitant medications). The clinical sequelae of HIV/HBV co-infection are multiple and can cause an increase in morbidity and mortality. Awareness of HBV/HIV co-infection with appropriate diagnosis and management is imperative for improved care of our HIV patients.
Keywords
Metrics
Total abstract views: 1360Total article views: 586
Crossref Citations
1. Prevalence of Hepatitis B and Hepatitis C Coinfections in an Adult HIV Centre Population in Gaborone, Botswana
Michael Tolle, Gabriel Anabwani, Stephanie Davis, Vincent Mabikwa, Premal Patel
The American Journal of Tropical Medicine and Hygiene vol: 85 issue: 2 first page: 390 year: 2011
doi: 10.4269/ajtmh.2011.10-0510